These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33145028)

  • 21. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels.
    Yoon DY; Lee S; Ban MS; Jang IJ; Lee S
    Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
    Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
    Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring.
    Haufroid V; Picard N
    Ther Drug Monit; 2019 Apr; 41(2):121-130. PubMed ID: 30883506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Southeast Asian Pharmacogenomics Research Network (SEAPharm): Current Status and Perspectives.
    Chumnumwat S; Lu ZH; Sukasem C; Winther MD; Capule FR; Abdul Hamid AAAT; Bhandari B; Chaikledkaew U; Chanhom N; Chantarangsu S; Charoenyingwattana A; Hang TT; Hlaing TM; Htun KS; Jittikoon J; Le L; Mahasirimongkol S; Mohamed Noor DA; Shrestha J; Suwannoi L; Tragulpiankit P; Turongkaravee S; Wattanapokayakit S; Xangsayarath P; Yuliwulandari R; Zain SM; Chantratita W
    Public Health Genomics; 2019; 22(3-4):132-139. PubMed ID: 31587001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
    Otsubo Y
    Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomics courses in pharmacy school curricula.
    Haga SB; Moaddeb J
    Pharmacogenomics; 2019 Jun; 20(9):625-630. PubMed ID: 31250728
    [No Abstract]   [Full Text] [Related]  

  • 27. Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation?
    Fricke-Galindo I; Falfán-Valencia R
    Expert Rev Respir Med; 2022; 16(11-12):1145-1152. PubMed ID: 36416606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the Implementation of Pharmacogenomic Panel-Testing in Primary Care in the Netherlands Utilizing a Theoretical Framework.
    van der Wouden CH; Paasman E; Teichert M; Crone MR; Guchelaar HJ; Swen JJ
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32192029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics-based therapeutic recommendations--ready for clinical practice?
    Kirchheiner J; Fuhr U; Brockmöller J
    Nat Rev Drug Discov; 2005 Aug; 4(8):639-47. PubMed ID: 16056390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-
    Kisor DF; Petry NJ; Bright DR
    Pharmgenomics Pers Med; 2021; 14():569-577. PubMed ID: 34040417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
    Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM
    BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Survey of Pharmacogenomics Testing Among Physicians, Pharmacists, and Researchers From China.
    Guo C; Hu B; Guo C; Meng X; Kuang Y; Huang L; Wang D; Xu K; Zhao Y; Yang G; Cai W; Shu Y
    Front Pharmacol; 2021; 12():682020. PubMed ID: 34322018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review.
    B Tata E; A Ambele M; S Pepper M
    Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32858798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National survey of physicians' perspectives on pharmacogenetic testing in solid organ transplantation.
    Deininger KM; Tsunoda SM; Hirsch JD; Anderson H; Lee YM; McIlvennan CK; Page RL; Tran JN; Aquilante CL
    Clin Transplant; 2020 Oct; 34(10):e14037. PubMed ID: 32654213
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions.
    Klein ME; Parvez MM; Shin JG
    J Pharm Sci; 2017 Sep; 106(9):2368-2379. PubMed ID: 28619604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.
    Haga SB; LaPointe NM; Cho A; Reed SD; Mills R; Moaddeb J; Ginsburg GS
    Pharmacogenomics; 2014 Sep; 15(13):1677-86. PubMed ID: 25410893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan.
    Hikino K; Fukunaga K; Mushiroda T
    Drug Metab Pharmacokinet; 2018 Dec; 33(6):243-249. PubMed ID: 30360950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Application of Pharmacogenetics: Where are We Now?
    van Schaik RH;
    EJIFCC; 2013 Feb; 24(3):105-12. PubMed ID: 27683445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.